Over the years, the FDAzilla blog has published over 650 articles. We hope this compilation will serve as a resource for you and your company. It should also help orient you to the scope of the FDAzilla blog as you continue to follow our efforts to provide accessible FDA data and insights.
In June of 2019, we added 180 FDA 483s to our database of 27,500+ FDA inspection documents.
Former FDA Investigator Peter Baker gives insight to MHRA’s GXP guide for data integrity.
GMP expert Barbara W. Unger provides her assessment of CDER’s State of Pharmaceutical Quality Report.
Three warning letters were posted this week in the areas we cover: two for drugs and one for device GMP violations. Akorn also announced that they received a warning letter but it has not yet been published.
Can mindfulness influence data integrity? Discover the insights Julie Maurhoff, a Senior Director of GxP Compliance and Inspection Readiness at Ultragenyx Pharmaceutical, gained after researching the topic.
Unlike last week, warning letter enforcement is sparse this week with only one drug GMP warning letter, none to compounding pharmacies and none to device firms.
In May of 2019, we added 262 FDA 483s to our database of 27,500+ FDA inspection documents.
This was a busy week in contrast to the past two weeks in terms of posted warning letters. Seven drug warning letters and one device warning letter were posted.
SEARCH LESS KNOW MORE
The essential tool for compliance, regulatory, and quality professionals
